11/11/2026
There needs to be a lot more research for clinical trials for kids with Medulloblastoma 🩶🎗️
MEDULLOBLASTOMA:
A headache that doesn't go away. Repeated vomiting. A child who suddenly struggles to walk or maintain balance. Sometimes, these are more than ordinary childhood symptoms.
For some children, the diagnosis is Medulloblastoma, an aggressive brain tumor that requires urgent, carefully coordinated treatment.
Behind every diagnosis is a child whose life should be filled with school, games, and childhood dreams. And behind every treatment decision is a medical team working to protect not only that child's life, but also their future development.
Let's understand this disease and the important role of modern radiation therapy in its management.
1. WHAT IS MEDULLOBLASTOMA?
Medulloblastoma is a malignant embryonal tumor of the central nervous system (CNS) and one of the most common malignant brain tumors in children.
It typically originates in the cerebellum, the part of the brain responsible for coordination, balance, and motor control.
It is particularly common in young children, although it can occur at any age.
Unlike many other brain tumors, medulloblastoma has an important tendency to spread through the cerebrospinal fluid (CSF).
This means that tumor cells can travel from the primary tumor site and implant along the surfaces of the brain and spinal cord, producing what is known as leptomeningeal dissemination or drop metastases.
In some patients, metastatic deposits may be found along the spinal canal, making assessment of the entire craniospinal axis essential.
2. CLINICAL PRESENTATION: WHAT SHOULD WE LOOK FOR?
Symptoms are often related to increased intracranial pressure, cerebellar dysfunction, or obstruction of normal CSF circulation.
Common clinical presentations include:
- Persistent headaches, particularly in the morning.
- Nausea and recurrent vomiting.
- Unsteady walking and loss of balance (ataxia).
- Difficulty with coordination.
- Double vision or abnormal eye movements.
- Fatigue and changes in behavior.
- In some cases, hydrocephalus due to obstruction of the fourth ventricle.
Because the tumor frequently develops near the fourth ventricle, it can interfere with normal CSF circulation, leading to obstructive hydrocephalus.
3. UNDERSTANDING THE MOLECULAR SUBGROUPS
Medulloblastoma is not a single biological disease.
Modern molecular classification identifies four major molecular groups:
1. WNT-Activated Medulloblastoma
This subgroup generally has a favorable prognosis compared with the other major groups when treated appropriately.
2. SHH-Activated Medulloblastoma
Associated with abnormalities in the Sonic Hedgehog signaling pathway. Its clinical behavior varies according to age and additional molecular features, including TP53 status.
3. Group 3 Medulloblastoma
Often associated with MYC amplification in a subset of cases and generally considered biologically aggressive.
4. Group 4 Medulloblastoma
A common molecular subgroup with variable clinical behavior and a distinct pattern of genetic alterations.
These molecular subgroups are important because they help clinicians understand tumor biology, estimate prognosis, and develop more individualized treatment strategies.
4. HOW IS MEDULLOBLASTOMA DIAGNOSED?
Accurate diagnosis and staging are essential before treatment begins.
The diagnostic workup generally includes:
MRI Brain with Contrast
Used to identify the primary tumor, evaluate its relationship with surrounding structures, and assess possible hydrocephalus.
MRI of the Entire Spine
Essential for evaluating possible leptomeningeal dissemination and spinal drop metastases.
Histopathological Examination
Confirms the diagnosis and identifies the histological subtype, such as classic, desmoplastic/nodular, or large-cell/anaplastic medulloblastoma.
Molecular Testing
Helps identify the molecular subgroup and relevant genetic alterations.
CSF Cytology
Used to detect tumor cells in the cerebrospinal fluid when clinically appropriate. Its timing is important, and sampling is generally performed after surgery when it is safe to do so.
Disease dissemination is also assessed using the Chang M staging system, which describes the extent of metastatic spread.
5. HOW IS MEDULLOBLASTOMA TREATED?
Treatment requires a multidisciplinary approach involving pediatric neurosurgery, pediatric oncology, radiation oncology, medical physics, radiology, and pathology.
The main treatment modalities are:
A. SURGERY
The initial treatment usually involves maximal safe surgical resection.
The objectives are to obtain tissue for diagnosis, remove as much tumor as safely possible, and relieve pressure on surrounding structures.
However, complete removal should never come at the expense of unacceptable neurological injury, particularly when the tumor is closely associated with the brainstem or critical structures.
B. CHEMOTHERAPY
Chemotherapy is an essential component of treatment for many children.
Common agents include:
- Cisplatin.
- Vincristine.
- Cyclophosphamide.
- Lomustine (CCNU).
The exact regimen depends on the patient's age, risk group, molecular findings, and treatment protocol.
C. RADIOTHERAPY
This is one of the most important components of treatment for many children with medulloblastoma, particularly those old enough to receive craniospinal irradiation.
And unlike many other localized brain tumors, treating only the primary tumor may not be sufficient because medulloblastoma can spread through the CSF.
This brings us to one of the most important concepts in pediatric radiation oncology.
6. WHY IS CRANIOSPINAL IRRADIATION (CSI) SO IMPORTANT?
Craniospinal Irradiation is a specialized radiation technique designed to treat the entire subarachnoid space surrounding the brain and spinal cord.
Its purpose is to treat both the primary disease region and potential microscopic tumor dissemination throughout the CSF pathways.
CSI generally includes:
- The entire brain.
- The meninges and intracranial CSF spaces.
- The spinal canal and spinal CSF spaces.
- The appropriate spinal and vertebral treatment volume according to the patient's skeletal maturity and treatment protocol.
After CSI, an additional radiation dose, known as a Boost, is delivered to the primary tumor bed.
Selected patients with visible metastatic deposits may also require additional boosts to those sites.
7. RADIOTHERAPY DOSES: AVERAGE-RISK VS HIGH-RISK
Radiotherapy doses are determined by the patient's clinical and biological risk classification.
For children generally older than 3–4 years, depending on the protocol:
Average-Risk Medulloblastoma
A commonly used approach includes:
- CSI: 23.4 Gy in 13 fractions.
- Tumor bed boost: Additional 30.6 Gy.
- Total primary-site dose: 54 Gy.
High-Risk Medulloblastoma
A commonly used approach includes:
- CSI: 36 Gy in 20 fractions.
- Tumor bed boost: Additional 18–19.8 Gy.
- Total primary-site dose: 54–55.8 Gy.
These are representative treatment schedules, not universal prescriptions. Specific protocols may modify the doses, target volumes, and boost strategy according to metastatic status, histology, molecular features, and treatment response.
8. WHY IS AGE SO IMPORTANT IN PEDIATRIC MEDULLOBLASTOMA?
One of the greatest challenges in treating young children is balancing tumor control with the long-term effects of radiation.
The developing brain is particularly sensitive to radiation exposure.
Children younger than approximately 3 years are often managed with radiation-sparing strategies, initially using surgery and chemotherapy to delay or sometimes avoid radiotherapy.
However, this is not an absolute rule.
The decision depends on the molecular subgroup, histology, disease dissemination, response to chemotherapy, and the child's neurological development.
The ultimate goal is to achieve disease control while reducing the risk of long-term neurodevelopmental complications.
9. MODERN RADIOTHERAPY TECHNIQUES AND TREATMENT PLANNING
Delivering CSI in children is technically challenging.
The treatment field must cover the entire craniospinal axis while maintaining appropriate dose uniformity and minimizing exposure to healthy organs.
Modern treatment techniques include:
3D Conformal Radiotherapy (3D-CRT)
Traditionally used for craniospinal irradiation, with careful management of field junctions and dose distribution.
Intensity-Modulated Radiation Therapy (IMRT)
Allows modulation of radiation intensity to improve dose conformity and protect selected organs at risk.
Volumetric Modulated Arc Therapy (VMAT)
Can provide highly conformal treatment through rotational delivery and may help manage complex craniospinal target volumes.
Proton Therapy
Protons offer a major dosimetric advantage in selected pediatric patients because of their characteristic Bragg peak and reduced exit dose.
This can reduce unnecessary radiation exposure to healthy tissues outside the target volume, which is particularly relevant in children expected to survive for many years.
However, proton therapy requires careful consideration of range uncertainty, robustness, and treatment geometry.
10. ORGANS AT RISK: PROTECTING THE CHILD'S FUTURE
During CSI planning, several organs require particular attention:
- Cochleae: To reduce the risk of radiation-associated hearing impairment.
- Thyroid gland: To reduce the risk of hypothyroidism.
- Heart and lungs: Especially during spinal treatment.
- Esophagus and bowel: Depending on the treatment technique and field arrangement.
- Kidneys: Particularly relevant to posterior spinal field arrangements.
- Pituitary and hypothalamus: Important for long-term endocrine function.
- Developing vertebral bodies: To reduce the risk of asymmetric growth.
- Brain and healthy neural structures: To minimize long-term neurocognitive effects.
Long-term follow-up is essential because survivors may experience hearing impairment, endocrine dysfunction, growth abnormalities, neurocognitive difficulties, or secondary malignancies.
11. WHAT IS THE ROLE OF THE RADIATION THERAPIST?
Behind every successful treatment delivery is a team responsible for accuracy and patient safety.
For pediatric medulloblastoma, the radiation therapist plays a particularly important role in:
- Reproducible patient positioning.
- Immobilization using an appropriate thermoplastic mask.
- Accurate daily setup and image verification.
- Monitoring treatment-field alignment and field junctions.
- Maintaining patient comfort and safety.
- Supporting children who may feel frightened or anxious during treatment.
Treating a child requires more than technical precision.
It requires patience, communication, and an understanding that every treatment session may be a completely new experience for a young patient.
Medulloblastoma is an aggressive childhood brain tumor, but advances in neurosurgery, chemotherapy, molecular classification, and modern radiation therapy have significantly improved treatment outcomes.
Craniospinal irradiation remains a cornerstone of treatment for many eligible children because the disease has the ability to spread through the cerebrospinal fluid.
But our responsibility goes beyond controlling the tumor.
We must protect the developing brain, preserve hearing, minimize late effects, and give every child the best possible chance of returning to a normal childhood.
WE ARE NOT JUST TREATING A BRAIN TUMOR. WE ARE PROTECTING A CHILD'S FUTURE.
❤️☢️
---
SCIENTIFIC REFERENCES
1. National Cancer Institute (NCI). Childhood Medulloblastoma and Other CNS Embryonal Tumors Treatment (PDQ®) – Health Professional Version.
2. SIOP-Europe and European Reference Network. Medulloblastoma therapy: Consensus treatment recommendations. European Journal of Cancer Paediatric Oncology. 2024.
3. National Comprehensive Cancer Network (NCCN). Pediatric Central Nervous System Cancers, Version 2.2025.
4. The Royal College of Radiologists. Radiotherapy Dose Fractionation, 4th Edition. 2024.
5. World Health Organization. WHO Classification of Tumours of the Central Nervous System, 5th Edition.